Press coverage about Bioanalytical Systems (NASDAQ:BASI) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioanalytical Systems earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.8220805079352 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, TheStreet raised shares of Bioanalytical Systems from a “d+” rating to a “c” rating in a research note on Wednesday.
Bioanalytical Systems traded up $0.04, hitting $1.70, during trading hours on Friday, MarketBeat Ratings reports. 11,646 shares of the stock were exchanged, compared to its average volume of 25,690. The company has a quick ratio of 0.59, a current ratio of 0.72 and a debt-to-equity ratio of 0.53. Bioanalytical Systems has a 12 month low of $1.37 and a 12 month high of $2.95.
Bioanalytical Systems (NASDAQ:BASI) last released its quarterly earnings results on Tuesday, May 15th. The company reported $0.01 EPS for the quarter. Bioanalytical Systems had a net margin of 2.35% and a return on equity of 6.39%. The business had revenue of $5.94 million for the quarter.
About Bioanalytical Systems
Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through Contract Research Services and Research Products segments.
Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.